Online inquiry

IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ12941MR)

This product GTTS-WQ12941MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 0 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets MUC1 gene. The antibody can be applied in Solid tumors research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 0
Species Humanized
RefSeq NM_001018016.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4582
UniProt ID P15941
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MUC1, PankoMab(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ12941MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ3108MR IVTScrip™ mRNA-Anti-B4GALNT1, APN311(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA APN311
GTTS-WQ4412MR IVTScrip™ mRNA-Anti-TNFRSF9, BMS-663513(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BMS-663513
GTTS-WQ14374MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA r-hTBP-1
GTTS-WQ8871MR IVTScrip™ mRNA-Anti-IFNA1&IFNB1, IFN-alpha-REC(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA IFN-alpha-REC
GTTS-WQ3921MR IVTScrip™ mRNA-Anti-CD274, BCD-135(Cap 0, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BCD-135
GTTS-WQ13693MR IVTScrip™ mRNA-Anti-ERBB2, RC48(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA RC48
GTTS-WQ7444MR IVTScrip™ mRNA-Anti-ITGA2, GBR500(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA GBR500
GTTS-WQ6967MR IVTScrip™ mRNA-Anti-VEGFA, ESBA-1008(Cap 0, 5-Methyl-CTP, 120 nt-poly(A)) mRNA ESBA-1008
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW